Pharmacokinetics of dopamine in healthy male subjects. 2000

D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1009, USA. dmacg@wfubmc.edu

BACKGROUND Dopamine is an agonist of alpha, beta, and dopaminergic receptors with varying hemodynamic effects depending on the dose of drug being administered. The purpose of this study was to measure plasma concentrations of dopamine in a homogeneous group of healthy male subjects to develop a pharmacokinetic model for the drug. Our hypothesis was that dopamine concentrations can be predicted from the infusion dose using a population-based pharmacokinetic model. METHODS Nine healthy male volunteers aged 23 to 45 yr were studied in a clinical research facility within our academic medical center. After placement of venous and arterial catheters, dopamine was infused at 10 microg x kg(-1) x min(-1) for 10 min, followed by a 30-min washout period. Subsequently, dopamine was infused at 3 microg x kg(-1) x min(-1) for 90 min, followed by another 30-min washout period. Timed arterial blood samples were centrifuged, and the plasma was analyzed by high-performance liquid chromatography. Mixed-effects pharmacokinetic models using NONMEM software (NONMEM Project Group, University of California, San Francisco, CA) were used to determine the optimal compartmental pharmacokinetic model for dopamine. RESULTS Plasma concentrations of dopamine varied from 12,300 to 201,500 ng/l after 10 min of dopamine infusion at 10 microg x kg(-1) x min(-1). Similarly, steady-state dopamine concentrations varied from 1,880 to 18,300 ng/l in these same subjects receiving 3-microg x kg(-1) x min(-1) infusions for 90 min. A two-compartment model adjusted for body weight was the best model based on the Schwartz-Bayesian criterion. CONCLUSIONS Despite a homogeneous population of healthy male subjects and weight-based dosing, there was 10- to 75-fold intersubject variability in plasma dopamine concentrations, making standard pharmacokinetic modeling of less utility than for other drugs. The data suggest marked intraindividual and interindividual variability in dopamine distribution and/or metabolism. Thus, plasma dopamine concentrations in patients receiving dopamine infusion at identical rates may vary profoundly. Our data suggest that dosing dopamine based on body weight does not yield predictable blood concentrations.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
June 2000, Journal of psychopharmacology (Oxford, England),
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
May 2009, European journal of clinical pharmacology,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
May 2004, Drug metabolism and disposition: the biological fate of chemicals,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
December 2012, Chirality,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
April 1996, Biopharmaceutics & drug disposition,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
January 2009, Pakistan journal of pharmaceutical sciences,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
May 2007, British journal of clinical pharmacology,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
January 1984, European journal of clinical pharmacology,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
May 1992, Biopharmaceutics & drug disposition,
D A MacGregor, and T E Smith, and R C Prielipp, and J F Butterworth, and R L James, and P E Scuderi
January 2007, Arzneimittel-Forschung,
Copied contents to your clipboard!